Abatacept in Treating Adults With Mild Relapsing Wegener's Granulomatosis

Inclusion Criteria

• •Diagnosis of WG, meeting at least 2 of the 5 modified American College of Rheumatology (ACR) criteria. More information about this criterion can be found in the protocol.
• •Relapse of WG within the past 28 days where disease activity is confined to one or more of the following sites and where the symptoms/signs are of such a nature that the usual treatment would consist of the reinstitution or increase in GC to no more than prednisone 30mg daily and/or an increase or addition of a second immunosuppressive agent other than CYC (more specific information about this criterion can be found in the protocol):
• •1. Sinonasal disease
• •2. Oral mucosa ulceration
• •3. Skin disease
• •4. Musculoskeletal disease
• •5. Pulmonary parenchymal disease
• •6. Mild ocular disease
• •7. Subglottic inflammation without significant stenosis
• •8. Otic disease
• •9. Breast involvement
• •10. Urogenital involvement
• •11. Other mild disease
• •Age of 15 years or older
• •Willing and able to undergo treatment and attend follow-up visits
• •Willing to use effective forms of contraception throughout the study
• •Active infection
• •HIV infected, hepatitis C virus infected, or positive for hepatitis B
• •Unable to follow through with study participation
• •Cytopenia, defined as platelet count less than 80,000/mm3, absolute neutrophil count less than 1500/mm3, OR hematocrit less than 20%
• •Kidney insufficiency
• •Use of illegal drugs
• •Any other uncontrolled disease that would prevent participation
• •History of cancer. More information about this criterion can be found in the protocol.
• •Received an investigational medication or procedure within 30 days of study entry
• •Received a live vaccine within 4 weeks of study entry
• •Positive tuberculin skin test. More information about this criterion can be found in the protocol.
• •Tuberculosis as indicated by radiographic evidence
• •Past treatment with rituximab within the past 12 months, or past treatment with rituximab more than 12 months ago where the B lymphocyte count has not returned to normal
• •Certain other diseases. More information about this criterion can be found in the protocol.
• •Pregnant or breastfeeding